Here are 1-3 brief analogies for Phio Pharmaceuticals:

• Alnylam Pharmaceuticals for cancer immunotherapy. (Focuses on Phio's gene-regulating technology applied to cancer.)
• A biotech developing next-generation checkpoint inhibitor therapies, like an innovative competitor to Merck (Keytruda) or BMS (Opdivo). (Highlights Phio's work on immune checkpoint proteins with new approaches.)
• Moderna, but focused on novel gene-regulating treatments for cancer instead of vaccines. (Emphasizes Phio as an innovative biotech leveraging genetic technology for cancer therapeutics.)

• INTASYL therapeutic platform: A platform focused on targeting tumor and immune cells by regulating genes of the immune system.
• PH-762: An investigational therapeutic that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1.
• PH-894: An investigational therapeutic designed to silence the epigenetic protein BRD4, an intracellular regulator of gene expression.
• PH-804: An investigational therapeutic that targets the suppressive immune receptor TIGIT, a checkpoint protein present on T cells and natural killer cells.

Based on the provided description, Phio Pharmaceuticals Corp. is a biopharmaceutical company primarily focused on the research and development of immuno-oncology therapeutics. The company is developing various drug candidates (PH-762, PH-894, PH-804) and utilizes its INTASYL therapeutic platform. It also engages in collaborations for clinical development, such as with AgonOx Inc.

As Phio Pharmaceuticals is in the drug development and clinical trial phase, with no mention of commercialized products on the market, it does not currently have major commercial customers in the traditional sense (i.e., companies or individuals purchasing its products or services). Its activities are centered on R&D, potential licensing, partnerships, and advancing its therapeutic pipeline toward commercialization.

The key risks to Phio Pharmaceuticals (PHIO) are:

1. Clinical Development and Regulatory Approval Risks: As a clinical-stage biopharmaceutical company, Phio Pharmaceuticals' success is highly dependent on the successful development and regulatory approval of its product candidates, particularly PH-762. Risks include the potential for failed or inconclusive clinical trials, the time-consuming and uncertain nature of advancing product candidates through various clinical stages, and the challenges of obtaining necessary regulatory filings and approvals from authorities like the FDA. Adverse side effects or safety concerns identified during clinical trials could lead to the suspension or termination of these trials, significantly impacting the company's prospects.

2. Funding and Financial Stability: Phio Pharmaceuticals has a history of recurring losses from operations and anticipates continued negative cash flows in the foreseeable future. The company requires substantial capital to fund its ongoing research and development activities and clinical programs. There is a continuous risk that Phio may not be able to secure sufficient additional financing on acceptable terms, or at all. A failure to obtain adequate funding could force the company to delay, reduce the scope of, or abandon its development efforts. Moreover, raising capital through equity offerings could result in significant dilution for existing shareholders.

3. Commercialization and Market Acceptance Risks: Even if Phio Pharmaceuticals successfully develops and obtains regulatory approval for its product candidates, there is no guarantee of commercial success. The immuno-oncology market is highly competitive and rapidly evolving, with numerous established pharmaceutical and biotechnology companies. The company faces risks related to the adoption of its products by healthcare providers and patients, competition from existing or new therapies, and the ability to effectively manufacture, market, and distribute its products. Lack of market acceptance or an inability to compete effectively could significantly hinder revenue generation and overall financial performance.

Phio Pharmaceuticals Corp. (PHIO) is developing immuno-oncology therapeutics, with its main products being PH-762 (targeting PD-1), PH-894 (silencing BRD4), and PH-804 (targeting TIGIT), all for use in adoptive cell transfer (ACT).

PH-762 (PD-1 Inhibitor)

The global market for PD-1 and PD-L1 inhibitors, which PH-762 targets, was valued at approximately USD 64.53 billion in 2026 and is projected to reach USD 208.06 billion by 2032. Specifically, the PD-1 segment alone within the immune checkpoint inhibitors market was valued at USD 48.5 billion in 2025. North America holds a significant share of this market, with the PD-1 and PD-L1 inhibitor market in the region expected to be valued at around USD 27.56 billion by 2025.

PH-894 (BRD4 Silencer)

null

PH-804 (TIGIT Inhibitor)

The global TIGIT antibody market, which PH-804 targets, was valued at USD 1,520.75 million in 2025 and is projected to reach USD 4,985.40 million by 2032. North America is the fastest-growing region in this market, with the United States holding the largest share globally.

Adoptive Cell Therapy Market (General Context)

As all of Phio Pharmaceuticals' main products are for use in adoptive cell transfer (ACT), the broader adoptive cell therapy market is also relevant. The global adoptive cell therapy market was valued at USD 12.45 billion in 2026 and is forecast to reach USD 22.4 billion by 2033. North America is expected to dominate this market, holding a 42.7% share in 2026.

1. Successful Clinical Development and Potential Market Approval of PH-762: The company's lead product candidate, PH-762, is currently undergoing a Phase 1b dose-escalating clinical trial for cutaneous squamous cell carcinoma (cSCC), melanoma, and Merkel cell carcinoma. Positive results from this trial, including reported complete and partial responses in cSCC patients, are crucial for its progression to later-stage clinical trials and eventual market approval. The company expects to complete enrollment of all patients in the study in the third quarter of 2025. The successful development and regulatory approval of PH-762, especially given the significant unmet need and addressable market in cSCC, would be a primary driver of future revenue.
2. Advancement of Additional Pipeline Candidates (PH-894 and PH-804): Beyond PH-762, Phio Pharmaceuticals has other promising candidates in its INTASYL therapeutic platform. PH-894, a BRD4 silencer, has completed IND-enabling studies and has demonstrated dual action in tumor killing and immune activation with a favorable toxicology profile. PH-804 targets the suppressive immune receptor TIGIT. The continued progression of these candidates through preclinical and early clinical development stages could provide additional future revenue streams through licensing agreements or eventual commercialization, expanding the company's market opportunities.
3. Establishment of Strategic Partnerships and Licensing Agreements: As a clinical-stage biotechnology company, Phio Pharmaceuticals relies on capital to fund its research and development. While the company has secured financing to sustain operations into the first half of 2027, strategic partnerships and licensing agreements are vital for accelerating the development and commercialization of its INTASYL platform and drug candidates. The potential for securing partnership agreements to advance its pipeline, particularly PH-762, is seen as a key enhancer of the company's outlook. Such collaborations could provide non-dilutive funding, access to broader development capabilities, and established commercialization channels, ultimately enabling future revenue generation.

Share Issuance

• Phio Pharmaceuticals has experienced substantial dilution, with shares outstanding growing by 143.2% in the past year.
• In 2025, the company generated approximately $23.7 million in net proceeds from equity financings and warrant exercises.
• The number of shares outstanding increased significantly from 125,321 in November 2021 to 10.76 million by November 2025.

Inbound Investments

• In 2025, Phio Pharmaceuticals secured approximately $23.7 million in net proceeds from equity financings and warrant exercises, which strengthened its balance sheet.
• Institutional investors purchased 59,840 shares in the last 24 months, representing approximately $83.77K in transactions.
• Currently, 57.31% of Phio Pharmaceuticals' stock is owned by institutional investors.

Capital Expenditures

• Capital expenditures in the last 12 months (as of approximately year-end 2025) were -$12,000.
• The company's Capital Expenditure Compound Annual Growth Rate (CAGR) averaged -20.61% over the past 5 years.
• Phio Pharmaceuticals' latest trailing twelve months (TTM) CapEx CAGR stands at -14.43%.